Development and validation of a novel mRNA signature for predicting early relapse in non-small cell lung cancer
| العنوان: | Development and validation of a novel mRNA signature for predicting early relapse in non-small cell lung cancer |
|---|---|
| المؤلفون: | Jingping Lin, Jieping Huang, Cuibo Lin, Jinsen Weng, Shaofeng Lin, Shen Zhang, Haizhou Ji, Chunxia Zhang, Xi Ke, Chuanpeng Dong |
| المصدر: | Japanese Journal of Clinical Oncology. 51:1277-1286 |
| بيانات النشر: | Oxford University Press (OUP), 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, 03 medical and health sciences, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Internal medicine, Biomarkers, Tumor, Humans, Medicine, Radiology, Nuclear Medicine and imaging, RNA, Messenger, Stage (cooking), Propensity Score, Lung cancer, Cause of death, Receiver operating characteristic, Proportional hazards model, business.industry, Gene Expression Profiling, Reproducibility of Results, Cancer, General Medicine, Gene signature, medicine.disease, 030104 developmental biology, 030220 oncology & carcinogenesis, Propensity score matching, Neoplasm Recurrence, Local, business |
| الوصف: | Background Recurrence after initial primary resection is still a major and ultimate cause of death for non-small cell lung cancer patients. We attempted to build an early recurrence associated gene signature to improve prognostic prediction of non-small cell lung cancer. Methods Propensity score matching was conducted between patients in early relapse group and long-term survival group from The Cancer Genome Atlas training series (N = 579) and patients were matched 1:1. Global transcriptome analysis was then performed between the paired groups to identify tumour-specific mRNAs. Finally, using LASSO Cox regression model, we built a multi-gene early relapse classifier incorporating 40 mRNAs. The prognostic and predictive accuracy of the signature was internally validated in The Cancer Genome Atlas patients. Results A total of 40 mRNAs were finally identified to build an early relapse classifier. With specific risk score formula, patients were classified into a high-risk group and a low-risk group. Relapse-free survival was significantly different between the two groups in both discovery (HR: 3.244, 95% CI: 2.338-4.500, P Conclusions We successfully established a reliable signature for predicting early relapse in stage I–III non-small cell lung cancer. |
| تدمد: | 1465-3621 |
| DOI: | 10.1093/jjco/hyab075 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55d9220726577d2e897d22d0a2c0e8cb https://doi.org/10.1093/jjco/hyab075 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....55d9220726577d2e897d22d0a2c0e8cb |
| قاعدة البيانات: | OpenAIRE |
كن أول من يترك تعليقا!